Establishment of a normal-derived estrogen receptor-positive cell line comparable to the prevailing human breast cancer subtype.

Establishment of a normal-derived estrogen receptor-positive cell line comparable to the prevailing human breast cancer subtype.

Oncotarget. 2017 Jan 06;:

Authors: Hopkinson BM, Klitgaard MC, Petersen OW, Villadsen R, Rønnov-Jessen L, Kim J

Abstract
Understanding human cancer increasingly relies on insight gained from subtype specific comparisons between malignant and non-malignant cells. The most frequent subtype in breast cancer is the luminal. By far the most frequently used model for luminal breast cancer is the iconic estrogen receptor-positive (ERpos) MCF7 cell line. However, luminal specific comparisons have suffered from the lack of a relevant non-malignant counterpart. Our previous work has shown that transforming growth factor-β receptor (TGFβR) inhibition suffices to propagate prospectively isolated ERpos human breast luminal cells from reduction mammoplasties (HBEC). Here we demonstrate that transduction of these cells with hTERT/shp16 renders them immortal while remaining true to the luminal lineage including expression of functional ER (iHBECERpos). Under identical culture conditions a major difference between MCF7 and normal-derived cells is the dependence of the latter on TGFβR inhibition for ER expression. In a breast fibroblast co-culture model we further show that whereas MCF7 proliferate concurrently with ER expression, iHBECERpos form correctly polarized acini, and segregate into proliferating and ER expressing cells. We propose that iHBECERpos may serve to shed light on hitherto unappreciated differences in ER regulation and function between normal breast and breast cancer.

PMID: 28076334 [PubMed - as supplied by publisher]

http://ift.tt/2j42nBa